Vidalista is an India-market brand family associated with tadalafil in catalogs linked to Centurion Laboratories. Company-linked listings describe conventional tablets at multiple strengths and additional products carrying names such as Vidalista CT, Vidalista Professional and Vidalista Super Active. These are not interchangeable identity claims: dosage form, ingredients and documentation must be verified for each variant.
The available catalog is useful but imperfect evidence. Some Vidalista-related cards contain inconsistent manufacturer fields, unrelated sildenafil text or copied product descriptions. Those defects mean a listed name and strength can be reported cautiously, but the page should not claim every photograph or reseller listing is authentic or that all products share one verified specification. In particular, a high advertised strength is not a U.S. labeled ED dosage recommendation.
This is a foreign-product identity page, not a U.S. pharmacy offer. For other brands see the Indian tadalafil directory. For lawful domestic product options, FDA-approved U.S. generics and Cialis are distinct regulated categories. No foreign-market Vidalista variant should be portrayed as FDA-approved because tadalafil itself has approved U.S. uses.
Centurion-associated records identify Vidalista-branded tadalafil tablets, including lower-strength and higher-strength marketed presentations. The family name alone does not establish whether a particular package is a standard film-coated tablet, a chewable presentation or a different product.
Record the exact suffix and claimed composition before describing a specific item. For example, Vidalista 20 and Vidalista CT 20 should not be merged into one FDA-equivalent product solely because their advertised numbers match. Centurion also lists Super Vidalista as a tadalafil–dapoxetine combination, not a plain tadalafil strength; the source contains inconsistent numerical descriptions of that combination.
Company-linked records describe standard tablets, a CT chewable listing, Professional products described as sublingual, Super Active capsules, and a separately named Super Vidalista tablet combining tadalafil with dapoxetine. These are company marketing records, not independently verified bioequivalence or batch authentication. Numerical details in the Super Vidalista listing conflict between structured fields and narrative text, so this article does not assign a definitive two-drug strength from that record.
Some entries are visibly inconsistent, including references to sildenafil on a tadalafil product card. These conflicts lower confidence in secondary fields and make pack-level evidence important.
| Variant or listing | Reported characteristics | Editorial confidence |
|---|---|---|
| Vidalista 5 / 10 / 20 mg | Tadalafil tablets in Centurion-linked listings | Company-linked product-name and ingredient claim |
| Vidalista 2.5 / 40 / 60 mg | Additional strengths advertised in the catalog | Reported; exact pack and status require review |
| Vidalista CT 20 | Chewable tablet claim | Dosage form must be checked independently |
| Vidalista Professional 20 | Sublingual description in catalog | Special form; not U.S. tablet equivalence |
| Vidalista Super Active 20 | Capsule presentation claim | Form and authenticity require verification |
| Super Vidalista | Tadalafil plus dapoxetine in Centurion-linked listings | Different combination; numerical strength fields are inconsistent |
Centurion Laboratories Private Limited appears as the company associated with the catalog. This is a stronger basis for brand association than an anonymous global pharmacy advertisement. It is still necessary to distinguish a general manufacturer description from evidence that a specific marketed package, lot or reseller stock was made by that company.
If a field says “manufacturer: tadalafil” or conflicts with another product card, it should be treated as a catalog-quality issue, not converted into a certain corporate attribution for every variant.
Standard oral tadalafil tablets are a different research subject from CT chewables, purported sublingual Professional presentations or soft capsules. Route of administration can affect formulation requirements, and identical milligrams do not automatically establish identical absorption or substitutability.
Do not assume the active ingredients or absorption profile of a named special form from the ordinary Vidalista tablet listing. Super Vidalista is a more fundamental distinction: the company-linked composition includes the additional drug dapoxetine, so it does not belong in a single-ingredient tadalafil product range. Refer to the authenticated label of each presentation before publishing a dose or ingredient claim.
The Centurion-associated catalog includes marketed strengths above the conventional U.S. Cialis ED tablet lineup. Those numbers are relevant to identifying a foreign-market listing, but not to recommending the strongest tablet or comparing clinical effectiveness.
U.S. tadalafil labeling separates 2.5 and 5 mg daily contexts from 10 and 20 mg as-needed ED tablet contexts. The U.S. strengths guide owns that clinical catalogue; this page does not create alternative dosing advice.
Catalog family lists may mention Super Vidalista or other names alongside plain Vidalista tablets. A suffix can indicate a different medicine combination, presentation or marketing claim. Unless a product-specific source establishes the complete active-ingredient declaration, it is inaccurate to call it ordinary tadalafil.
Tadalafil combined with another agent creates additional clinical and regulatory questions. This page therefore avoids guessing a second ingredient from the trade name, while urging exact label verification.
An FDA-approved generic needs an approved application and appropriate equivalence assessment; a catalog naming tadalafil is not that assessment. Foreign marketing, manufacturing certifications and package photographs do not automatically establish authorization for U.S. dispensing.
U.S. patients can compare approved generic tadalafil with the Cialis-versus-generic comparison without treating Vidalista as part of the approved U.S. generic market.
Confirm the exact Vidalista suffix, active ingredients, reported strength, form, marketer or manufacturer attribution and country of marketing from a credible product record. A printed package should have internally consistent declarations, but appearance alone does not prove authenticity or regulatory approval.
Inconsistent catalog descriptions should be annotated as unresolved. Do not fill gaps by assuming that all Vidalista cards are correct or that a reseller has verified an obscure formulation.
If a product actually contains tadalafil, nitrates and riociguat are contraindicated, and alpha blockers, certain other cardiovascular medicines and metabolic interactions require review. A foreign-market pack may introduce additional uncertainty about its actual contents and purity.
The nitrate interaction guide addresses the urgent risk. No information here licenses self-treatment, dose escalation or concurrent use with sildenafil or vardenafil.
Online advertisements offering Vidalista to U.S. customers do not establish FDA approval, a lawful import pathway or pharmacy licensing. Routine imports of unapproved prescription drugs should not be marketed as interchangeable with normal U.S. dispensing.
For a legitimate prescription and pharmacy process, use the U.S. tadalafil buying guide. This article remains a product-identity reference and does not rank sellers, quote prices or promise stock.
Vidalista is an India-market tadalafil brand family in Centurion-linked catalogs. Products vary by form, and the separately named Super Vidalista is reported as tadalafil plus dapoxetine rather than plain tadalafil.
Centurion-associated catalogs list Vidalista products, but exact manufacturer roles and individual packages should be checked before making a batch-specific claim.
No equivalence should be assumed. CT is marketed as a chewable product and needs its own form and regulatory verification.
Centurion-linked listings describe a Professional sublingual presentation; that description is not proof of U.S. approval or interchangeability.
No. Their foreign catalog appearance does not make them U.S.-approved Cialis ED strength presentations.
Yes. Some listings contain inconsistent manufacturer fields and unrelated text, so uncertain details must be verified independently.
The foreign brand name and catalog alone do not establish a U.S. FDA-approved application.
Do not infer a lawful import or dispensing route. Clinician-prescribed FDA-approved U.S. tadalafil options are the appropriate comparison.